Delivery Characterization of SPL84 Inhaled Antisense Oligonucleotide Drug for 3849 + 10 kb C- > T Cystic Fibrosis Patients
Nucleic Acid Therapeutics · 01.10.2023 · 33 (5) · 306-318
DOI: 10.1089/nat.2023.0015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, online erschienen am 03.10.2023. Verfasst von Efrat Ozeri-Galai und 10 weiteren Autor:innen. Beteiligte Einrichtung: SpliSense, Biohouse Labs, Haddasah Ein Kerem, Jerusalem, Israel. Hauptthemen laut MEDLINE: Cystic Fibrosis. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Recent advances in the therapeutic potential of RNA-related treatments, specifically for antisense oligonucleotide (ASO)-based drugs, have led to increased numbers of ASO regulatory approvals. In this study, we focus on SPL84, an inhaled ASO-based drug, developed for the treatment of the pulmonary disease cystic fibrosis (CF). Pulmonary drug delivery is challenging, due to a variety of biological, physical, chemical, and structural barriers, especially when targeting the cell nucleus. The distribution of SPL84 throughout the lungs, penetration into the epithelial cells and nucleus, and structural stability are critical parameters that will impact drug efficacy in a clinical setting. In this study, we demonstrate broad distribution, as well as cell and nucleus penetration of SPL84 in mouse and monkey lungs. In vivo and in vitro studies confirmed the stability of our inhaled drug in CF patient-derived mucus and in lung lysosomal extracts. The mobility of SPL84 through hyperconcentrated mucus was also demonstrated. Our results, supported by a promising preclinical pharmacological effect of full restoration of cystic fibrosis transmembrane conductance regulator channel activity, emphasize the high potential of SPL84 as an effective drug for the treatment of CF patients. In addition, successfully tackling the lung distribution of SPL84 offers immense opportunities for further development of SpliSense's inhaled ASO-based drugs for unmet needs in pulmonary diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- SpliSense, Biohouse Labs, Haddasah Ein Kerem, Jerusalem, Israel.
- Marsico Lung Institute, UNC Chapel Hill, Chapel Hill, North Carolina, USA.
- Joint Department of Biomedical Engineering, UNC Chapel Hill, Chapel Hill, North Carolina, USA.
- Department of Genetics, The Hebrew University, Jerusalem, Israel.
ORCID-Profile: Ofra Barchad-Avitzur
Zitieren
APA
Ozeri-Galai, E., Friedman, L., Barchad-Avitzur, O., Markovetz, M. R., Boone, W., Rouillard, K. R., Stampfer, C. D., Oren, Y. S., Hill, D. B., Kerem, B., & Hart, G. (2023). Delivery Characterization of SPL84 Inhaled Antisense Oligonucleotide Drug for 3849 + 10 kb C- > T Cystic Fibrosis Patients. Nucleic Acid Therapeutics, 33(5), 306-318. https://doi.org/10.1089/nat.2023.0015
Vancouver
Ozeri-Galai E, Friedman L, Barchad-Avitzur O, Markovetz MR, Boone W, Rouillard KR, et al. Delivery Characterization of SPL84 Inhaled Antisense Oligonucleotide Drug for 3849 + 10 kb C- > T Cystic Fibrosis Patients. Nucleic Acid Therapeutics. 2023;33(5):306-318. doi:10.1089/nat.2023.0015
BibTeX
@article{OzeriGalai2023,
author = {Ozeri-Galai, Efrat and Friedman, Lital and Barchad-Avitzur, Ofra and Markovetz, Matthew R and Boone, William and Rouillard, Kaitlyn R and Stampfer, Chava D and Oren, Yifat S and Hill, David B and Kerem, Batsheva and Hart, Gili},
title = {Delivery Characterization of SPL84 Inhaled Antisense Oligonucleotide Drug for 3849 + 10 kb C- > T Cystic Fibrosis Patients},
journal = {Nucleic Acid Therapeutics},
year = {2023},
volume = {33},
number = {5},
pages = {306--318},
doi = {10.1089/nat.2023.0015}
}
EUVIMED